A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
The aim of the study is to compare progression-free survival (PFS) in previously treated
participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving
sotorasib 240 mg once daily (QD) and panitumumab vs investigator's choice (trifluridine and
tipiracil, or regorafenib), and sotorasib 960 mg once daily (QD) and panitumumab vs
investigator's choice (trifluridine and tipiracil, or regorafenib).
Colorectal Cancer (CRC)
trifluridine and tipiracil
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.